[go: up one dir, main page]

ES2494840T3 - Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas - Google Patents

Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas Download PDF

Info

Publication number
ES2494840T3
ES2494840T3 ES06723429.4T ES06723429T ES2494840T3 ES 2494840 T3 ES2494840 T3 ES 2494840T3 ES 06723429 T ES06723429 T ES 06723429T ES 2494840 T3 ES2494840 T3 ES 2494840T3
Authority
ES
Spain
Prior art keywords
seq
hbv
hepatitis
polynucleic acid
nucleoside analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06723429.4T
Other languages
English (en)
Inventor
Mithat Bozdayi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Fujirebio Europe NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Europe NV SA filed Critical Fujirebio Europe NV SA
Application granted granted Critical
Publication of ES2494840T3 publication Critical patent/ES2494840T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un ácido polinucleico de VHB aislado que codifica una variante de VHB, dicho ácido polinucleico de VHB comprende una mutación nucleotídica que produce sustitución de aminoácidos rtA181S del gen de la ADN polimerasa en la variante de VHB, en donde dicha mutación nucleotídica produce una sensibilidad disminuida al análogo de nucleósido adefovir y lamivudina, dicho ácido polinucleico de VHB comprende un ácido polinucleico elegido del grupo que consiste en SEQ ID 2, SEQ ID 3, SEQ ID 5, SEQ ID 6 y SEQ ID 7.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23

Claims (1)

  1. imagen1
    imagen2
ES06723429.4T 2005-03-15 2006-03-14 Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas Active ES2494840T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66148405P 2005-03-15 2005-03-15
EP05101997 2005-03-15
US661484P 2005-03-15
EP05101997 2005-03-15
PCT/EP2006/002352 WO2006097285A1 (en) 2005-03-15 2006-03-14 Hepatitis-b viral variants with reduced susceptibility to nucleoside analogs and uses thereof

Publications (1)

Publication Number Publication Date
ES2494840T3 true ES2494840T3 (es) 2014-09-16

Family

ID=35355552

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06723429.4T Active ES2494840T3 (es) 2005-03-15 2006-03-14 Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas

Country Status (10)

Country Link
US (1) US7422848B2 (es)
EP (1) EP1858916B1 (es)
JP (1) JP2008537483A (es)
CN (1) CN101203528A (es)
AU (1) AU2006224789B2 (es)
ES (1) ES2494840T3 (es)
NZ (1) NZ562467A (es)
PL (1) PL1858916T4 (es)
PT (1) PT1858916E (es)
WO (1) WO2006097285A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40233E1 (en) 1996-11-08 2008-04-08 Melbourne Health Viral variants and methods for detecting same
AUPO351996A0 (en) * 1996-11-08 1996-12-05 Western Health Care Network Viral variants and methods for detecting same
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
WO2003083094A1 (en) 2002-03-29 2003-10-09 Innogenetics N.V. Hbv drug resistance drug resistance detection methods
EP2455390A1 (en) * 2002-04-12 2012-05-23 Melbourne Health Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
AU2006224789B2 (en) 2005-03-15 2012-09-06 Innogenetics N.V. Hepatitis-B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
PT1858915E (pt) * 2005-03-15 2014-06-11 Justus Liebig Universität Giessen Variantes do vírus de hepatite b resistentes contra alguns análogos de nucleósido, mas sensíveis a outros, e suas utilizações
US8211443B2 (en) * 2005-04-08 2012-07-03 Melbourne Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
SG161255A1 (en) * 2005-04-08 2010-05-27 Melbourne Health Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof
KR101110013B1 (ko) * 2007-10-05 2012-02-29 (주)바이오니아 서열 내에 어베이직 부분을 포함하는 ｐｃｒ 증폭용프라이머
JP2009213465A (ja) * 2007-10-30 2009-09-24 Toshiba Corp Ｂ型肝炎ウイルス薬剤耐性株検出用核酸プライマーセット、アッセイキットおよびｂ型肝炎ウィルスの薬剤耐性株の検出方法
CA2950863C (en) 2014-06-02 2023-01-17 Isa Pharmaceuticals B.V. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
US9963751B2 (en) 2015-11-24 2018-05-08 The Penn State Research Foundation Compositions and methods for identifying agents to reduce hepatitis B virus covalently closed circular DNA
JP7558167B2 (ja) 2018-12-03 2024-09-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576175A (en) 1989-09-20 1996-11-19 Immuno Aktiengesellschaft Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen
US5858328A (en) 1991-06-04 1999-01-12 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection
US5849987A (en) 1992-06-02 1998-12-15 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection
DK0672136T3 (da) 1992-07-08 2000-08-21 Innogenetics Nv Polypeptider, der er afledt fra endonexin 2 og har hepatitis B virus-receptoraktivitet, og deres anvendelse i diagnostiske
US5595739A (en) 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6100068A (en) 1997-01-21 2000-08-08 Paik-Inje Memorial Institute For Biomedical Science Method of protein production using mitochondrial translation system
US5817457A (en) 1996-02-07 1998-10-06 Ma Bioservices, Inc. Methods and kits for detecting viral reverse transcriptase activity in a sample using an acidic pH or an elevated temperature
US5877162A (en) 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
ZA973367B (en) 1996-04-19 1997-11-18 Innogenetics Nv Method for typing and detecting HBV.
EP0907750B1 (en) 1996-04-26 2002-09-18 Massachusetts Institute Of Technology Three-hybrid screening assay
WO1998007869A1 (en) 1996-08-16 1998-02-26 Dong Wha Pharm. Ind. Co., Ltd. HBV POLYMERASE, RNase H ENZYME DERIVED FROM HBV POLYMERASE, PROCESSES FOR PREPARATION AND USES FOR SCREENING ANTIVIRAL AGENTS THEREOF
AUPO351996A0 (en) 1996-11-08 1996-12-05 Western Health Care Network Viral variants and methods for detecting same
US5939541A (en) 1997-03-28 1999-08-17 University Of South Carolina Method for enhancing expression of a foreign or endogenous gene product in plants
AU762355B2 (en) 1998-01-21 2003-06-26 Penn State Research Foundation, The Methods and compositions to investigate infection by hepatitis B virus and agents to prevent and treat the infection
US6150105A (en) 1998-08-20 2000-11-21 Genetic Assays, Inc. Methods of screening nucleic acids for nucleotide variations
JP2000270876A (ja) 1999-03-26 2000-10-03 Genome Science Laboratories Co Ltd Ｂ型肝炎ウイルス遺伝子の変異検出方法および検出キット
AUPP967999A0 (en) 1999-04-09 1999-05-06 North Western Health Care Network Viral variants
AU779112B2 (en) 1999-04-30 2005-01-06 Sequenom, Inc. Diagnostic sequencing by a combination of specific cleavage and mass spectrometry
EP2319917A3 (en) * 2002-02-07 2012-02-08 Melbourne Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
WO2003083094A1 (en) 2002-03-29 2003-10-09 Innogenetics N.V. Hbv drug resistance drug resistance detection methods
EP2455390A1 (en) 2002-04-12 2012-05-23 Melbourne Health Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
US20040191763A1 (en) 2002-10-01 2004-09-30 Gilead Sciences, Inc. HBV mutations associated with reduced susceptibility to adefovir
AU2006224789B2 (en) 2005-03-15 2012-09-06 Innogenetics N.V. Hepatitis-B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
PT1858915E (pt) 2005-03-15 2014-06-11 Justus Liebig Universität Giessen Variantes do vírus de hepatite b resistentes contra alguns análogos de nucleósido, mas sensíveis a outros, e suas utilizações

Also Published As

Publication number Publication date
PL1858916T3 (pl) 2015-01-30
EP1858916B1 (en) 2014-07-09
PL1858916T4 (pl) 2015-04-30
CN101203528A (zh) 2008-06-18
NZ562467A (en) 2011-07-29
JP2008537483A (ja) 2008-09-18
US20060234212A1 (en) 2006-10-19
PT1858916E (pt) 2014-10-06
AU2006224789B2 (en) 2012-09-06
US7422848B2 (en) 2008-09-09
WO2006097285A1 (en) 2006-09-21
EP1858916A1 (en) 2007-11-28
AU2006224789A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
ES2494840T3 (es) Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas
CN113423840B (zh) 多核苷酸无模板酶促合成中有效的产物裂解
US20200139335A1 (en) Enrichment of DNA Sequencing Libraries from Samples Containing Small Amounts of Target DNA
CY1120186T1 (el) Τροποποιημενα νουκλεοτιδια για αλληλουχιση πολυνουκλεοτιδιωn
ES2304739T3 (es) Metodos de genotipaje utilizando diferencias en la temperatura de fusion.
ATE557084T1 (de) Modifizierte dna-polymerasen zur verbesserten inkorporation von nukleotidanaloga
EP1963536A4 (en) POLYMERASES FOR NUCLEOTIDE ANALOGUE INSERTION
Jung et al. Development of RNA aptamer that inhibits methyltransferase activity of dengue virus
WO2008051530A3 (en) Polymerase enzymes and reagents for enhanced nucleic acid sequencing
WO2007016668A3 (en) Methods and compositions for disease prognosis based on nucleic acid methylation
MXPA02011896A (es) Produccion combinatoria de analogos de nucleotidos y nucleosidos (xitp).
Tedder et al. The ‘Red Queen’dilemma–running to stay in the same place: refections on the evolutionary vector of HBV in humans
Haasnoot et al. The Brome mosaic virus subgenomic promoter hairpin is structurally similar to the iron-responsive element and functionally equivalent to the minus-strand core promoter stem-loop C.
Furano et al. Cryptic genetic variation enhances primate L1 retrotransposon survival by enlarging the functional coiled coil sequence space of ORF1p
EP3684946B1 (en) Dna polymerase theta mutants, methods of producing these mutants, and their uses
EP1904518A4 (en) DNA POLYMERASE MIXTURES AND MUTANT DNA POLYMERASES
ES2562919T3 (es) Proteína y secuencia de ADN que codifica una actividad del tipo de la subtilisina adaptada al frío
JP2022543568A (ja) ポリヌクレオチドの鋳型なしの酵素による合成における長い配列の収量の増加
JP2019140953A5 (es)
JP2008534020A5 (es)
Umeda et al. Both heavy strand replication origins are active in partially duplicated human mitochondrial DNAs
WO2003093461A8 (fr) Banque genomique du cyanophage s-2l et analyse fonctionnelle
RU2009104533A (ru) Способы обнаружения болезни альцгеймера
Scott et al. Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus
ES2656055T3 (es) Procedimiento de amplificación transcripcional de ácidos nucleicos que reúne etapas de temperaturas diferentes